NCT06600412View on ClinicalTrials.gov

The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Diabetic Kidney Disease
Interventions
DRUG

R3R01

R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.

DRUG

Placebo

Please refer to arm/group description for further information.

Trial Locations (1)

2730

RECRUITING

Steno Diabetes Center Copenhagen, Copenhagen

All Listed Sponsors
collaborator

Region Hovedstadens Apotek

OTHER_GOV

collaborator

Copenhagen University Hospital at Herlev

OTHER

lead

River 3 Renal Corp.

INDUSTRY